Authors:
Keever-Taylor, CA
Bredeson, C
Loberiza, FR
Casper, JT
Lawton, C
Rizzo, D
Burns, WH
Margolis, DA
Vesole, DH
Horowitz, M
Zhang, MJ
Juckett, M
Drobyski, WR
Citation: Ca. Keever-taylor et al., Analysis of risk factors for the development of GVHD after T cell-depletedallogeneic BMT: Effect of HLA disparity, ABO incompatibility, and method of T-cell depletion, BIOL BLOOD, 7(11), 2001, pp. 620-630
Authors:
Drobyski, WR
Morse, HC
Burns, WH
Casper, JT
Sandford, G
Citation: Wr. Drobyski et al., Protection from lethal murine graft-versus-host disease without compromiseof alloengraftment using transgenic donor T cells expressing a thymidine kinase suicide gene, BLOOD, 97(8), 2001, pp. 2506-2513
Authors:
Filipovich, AH
Stone, JV
Tomany, SC
Ireland, M
Kollman, C
Pelz, CJ
Casper, JT
Cowan, MJ
Edwards, JR
Fasth, A
Gale, RP
Junker, A
Kamani, NR
Loechelt, BJ
Pietryga, DW
Ringden, O
Vowels, M
Hegland, J
Williams, AV
Klein, JP
Sobocinski, KA
Rowlings, PA
Horowitz, MM
Citation: Ah. Filipovich et al., Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant registry and the National Marrow Donor Program, BLOOD, 97(6), 2001, pp. 1598-1603
Authors:
Margolis, DA
Casper, JT
Segura, AD
Janczak, T
McOlash, L
Fisher, B
Miller, K
Gorski, J
Citation: Da. Margolis et al., Infiltrating T cells during liver graft-versus-host disease show a restricted T-cell repertoire, BIOL BLOOD, 6(4), 2000, pp. 408-415
Citation: Da. Margolis et Jt. Casper, Alternative-donor hematopoietic stem-cell transplantation for severe aplastic anemia, SEM HEMATOL, 37(1), 2000, pp. 43-55
Authors:
Davies, SM
Kollman, C
Anasetti, C
Antin, JH
Gajewski, J
Casper, JT
Nademanee, A
Noreen, H
King, R
Confer, D
Kernan, NA
Citation: Sm. Davies et al., Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the National Marrow Donor Program, BLOOD, 96(13), 2000, pp. 4096-4102
Citation: Rj. Orentas et al., Detection of Epstein-Barr virus EBER sequence in post-transplant lymphoma patients with DNA dendrimers, J VIROL MET, 77(2), 1999, pp. 153-163
Authors:
Chen, CL
Levine, A
Rao, A
O'Neill, K
Messinger, Y
Myers, DE
Goldman, F
Hurvitz, C
Casper, JT
Uckun, FM
Citation: Cl. Chen et al., Clinical pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-Genistein in patients with B-lineage lymphoid malignancies, J CLIN PHAR, 39(12), 1999, pp. 1248-1255